THE EFFECT OF DIETARY SUPPLEMENTATION WITH n-3 POLYUNSATURATED FATTY ACIDS ON THE SYNTHESIS OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR BY MONONUCLEAR CELLS

Stefan Endres, M.D., Reza Ghorbani, B.S., Vicki E. Kelley, Ph.D., Kostis Georgilis, M.D., Gerhard Lonnenmann, M.D., Jos W. M. van der Meer, M.D., Joseph G. Cannon, Ph.D., Tina S. Rogers, Ph.D., Mark S. Klempner, M.D., Peter C. Weber, M.D., Ernst J. Schaefer, M.D., Sheldon M. Wolff, M.D., and Charles A. Dinarello, M.D.

Abstract We examined whether the synthesis of interleukin-1 or tumor necrosis factor, two cytokines with potent inflammatory activities, is influenced by dietary supplementation with n−3 fatty acids.

Nine healthy volunteers added 18 g of fish-oil concentrate per day to their normal Western diet for six weeks. We used a radioimmunoassay to measure interleukin-1 (IL-1β and IL-1α) and tumor necrosis factor produced in vitro by stimulated peripheral-blood mononuclear cells. With endotoxin as a stimulus, the synthesis of IL-1β was suppressed from 7.4±0.9 ng per milliliter at baseline to 4.2±0.5 ng per milliliter after six weeks of supplementation (43 percent decrease; P = 0.048). Ten weeks after the end of n−3 supplementation, we observed a further decrease to 2.9±0.5 ng per milliliter (61 percent decrease; P = 0.005). The production of IL-1α and tumor necrosis factor responded in a similar manner. Twenty weeks after the end of supplementation, the production of IL-1β, IL-1α, and tumor necrosis factor had returned to the presupplement level. The decreased production of interleukin-1 and tumor necrosis factor was accompanied by a decreased ratio of arachidonic acid to eicosapentaenoic acid in the membrane phospholipids of mononuclear cells.

We conclude that the synthesis of IL-1β, IL-1α, and tumor necrosis factor can be suppressed by dietary supplementation with long-chain n−3 fatty acids. The reported antiinflammatory effect of these n−3 fatty acids may be mediated in part by their inhibitory effect on the production of interleukin-1 and tumor necrosis factor. (N Engl J Med 1989; 320:265-71.)

INTERLEUKIN-1 and tumor necrosis factor are polypeptide cytokines synthesized by monocytes and other cells in response to injury, as well as to infectious, inflammatory, or immunologic challenges.1-3 These cytokines induce local inflammatory changes and mediate several systemic acute-phase responses.4,5 Moreover, interleukin-1 and tumor necrosis factor often act synergistically — e.g., on vascular endothelium,6 insulin production,7 and the synthesis of metabolites of arachidonic acid.8

The n−3 (also called omega−3) fatty acids are polyunsaturated fatty acids in which the last double bond is located between the third and fourth carbon atom from the methyl end of the fatty acid chain. These fatty acids are scarce in a normal Western diet but make up an appreciable part of the fat intake in diets rich in cold-water fish and seal meat.9 Epidemiologic studies in populations of coastal Eskimo,10,11 Japanese,12 and Dutch13 subjects have shown that a high intake of n−3 fatty acids correlates with a low incidence of cardiovascular and inflammatory diseases such as asthma and Type I diabetes mellitus.11 The modification of the fatty acid composition of cell membranes and the formation of eicosanoids by dietary supplementation with n−3 fatty acids have subsequently been shown in human beings.14,15 In healthy volunteers16 and in patients with asthma,17 n−3 dietary supplementation results in decreased neutrophil chemotaxis and inhibited generation of leukotriene B₄ by neutrophils and monocytes. In clinical studies, dietary supplementation with n−3 fatty acids has led to improvements in patients with rheumatoid arthritis18 and in patients with psoriasis.19 Prospective studies in animals fed n−3 fatty acids support these clinical observations.20-23

Since interleukin-1 and tumor necrosis factor are the principal polypeptide mediators of inflammation,
METHODS

Subjects and Study Design

The study was approved by the Human Investigative Review Committee of the New England Medical Center Hospitals. Nine healthy male volunteers entered the study after giving informed consent (average age, 28 years; range, 21 to 39). The initial study group consisted of six volunteers, and a second group of three volunteers entered the study six months after the first group. Both groups were studied in the same fashion. Since the results were similar in the two groups, the data for the nine subjects are pooled in this report.

For six weeks, the subjects added 18 g of marine lipid concentrate (six capsules of MaxEPA three times per day, kindly provided by R.P. Scherer, Troy, Mich.) to their otherwise unchanged diets. By gas chromatography, the n-3 fatty acid content of 1 g of the lipid concentrate was shown to consist of 153 mg of eicosapentaenoic acid and 103 g of docosahexaenoic acid. The subjects were free of disease and refrained from taking any medications during the course of the study. Before supplementation, the subjects’ mean caloric intake ranged from 2000 to 3000 kcal per day. Six to 10 percent of the calories (mean, 28 g) were highly unsaturated fatty acids, but less than 1 percent were n-3 fatty acids. During supplementation, the intake of highly unsaturated fatty acids increased from 28 to 34 g.

The production of interleukin-1 and tumor necrosis factor by stimulated-blood mononuclear cells in vitro was assessed during four phases of the study: before the start of n-3 supplementation, during the 6th week of supplementation, and during the 10th and 20th weeks after the end of supplementation (the latter two phases being washout periods). To ascertain reproducibility, blood samples were obtained on three different days, two to three days apart, during each of the four phases of the study. The mean of these three replicate determinations was calculated and used for further analysis.

Stimulated-blood mononuclear cells in vitro were washed twice in 0.15 M sodium chloride, slides were prepared by cytocentrifugation, and their chemotactic response to synthetic leukotriene B4 (Sigma) was assessed twice, during week 1 and week 7. Blood samples were obtained on three different days, two to three days apart, during each of the four phases of the study. The mean of these three replicate determinations was calculated and used for further analysis.

Subjects and Study Design

The study was approved by the Human Investigative Review Committee of the New England Medical Center Hospitals. Nine healthy male volunteers entered the study after giving informed consent (average age, 28 years; range, 21 to 39). The initial study group consisted of six volunteers, and a second group of three volunteers entered the study six months after the first group. Both groups were studied in the same fashion. Since the results were similar in the two groups, the data for the nine subjects are pooled in this report.

For six weeks, the subjects added 18 g of marine lipid concentrate (six capsules of MaxEPA three times per day, kindly provided by R.P. Scherer, Troy, Mich.) to their otherwise unchanged diets. By gas chromatography, the n-3 fatty acid content of 1 g of the lipid concentrate was shown to consist of 153 mg of eicosapentaenoic acid and 103 g of docosahexaenoic acid. The subjects were free of disease and refrained from taking any medications during the course of the study. Before supplementation, the subjects’ mean caloric intake ranged from 2000 to 3000 kcal per day. Six to 10 percent of the calories (mean, 28 g) were highly unsaturated fatty acids, but less than 1 percent were n-3 fatty acids. During supplementation, the intake of highly unsaturated fatty acids increased from 28 to 34 g.

The production of interleukin-1 and tumor necrosis factor by stimulated-blood mononuclear cells in vitro was assessed during four phases of the study: before the start of n-3 supplementation, during the 6th week of supplementation, and during the 10th and 20th weeks after the end of supplementation (the latter two phases being washout periods). To ascertain reproducibility, blood samples were obtained on three different days, two to three days apart, during each of the four phases of the study. The mean of these three replicate determinations was calculated and used for further analysis.

Stimulated-blood mononuclear cells in vitro were washed twice in 0.15 M sodium chloride, slides were prepared by cytocentrifugation, and their chemotactic response to synthetic leukotriene B4 (Sigma) was assessed twice, during week 1 and week 7. Blood samples were obtained on three different days, two to three days apart, during each of the four phases of the study. The mean of these three replicate determinations was calculated and used for further analysis.

Stimulation of Mononuclear Cells in Vitro

Venous blood was drawn into syringes pretreated with heparin (20 U per milliliter), and the mononuclear-cell fraction was obtained by Ficol–Hypaque centrifugation. At the same time a sample of blood was obtained without heparin in order to prepare heat-inactivated (50°C, 40 minutes) serum. The mononuclear cells were washed twice in 0.15 M sodium chloride, slides were prepared by cytocentrifugation, and 100 cell-differential counts were performed in a blinded fashion on coded slides. RPMI-1640 culture medium (Whittaker M.A. Bioproducts, Walkersville, Md.), supplemented with 2 mM levo-glutamine, 100 U of penicillin per milliliter, and 100 μg of streptomycin per milliliter, was subjected to ultrafiltration to remove endotoxins, as described elsewhere. The mononuclear cells were suspended at a concentration of 5X10⁶ cells per milliliter in RPMI medium with 2 percent heat-inactivated autologous serum, and 100 μl was divided into aliquots in 96-well flat-bottomed microtiter plates. An equal volume of either serum-free RPMI or RPMI containing various stimulants was added. The cells were stimulated with endotoxin (lipopolysaccharide Escherichia coli 055:B5, Sigma, St. Louis) at 1 and 10 ng per milliliter, phytohemagglutinin (Difco, Detroit) at 3 μg per milliliter, or heat-killed Staphylococcus epidermidis, opsonized with 2.5 percent fresh autologous serum, at 20 bacteria per mononuclear cell. After incubation for 24 hours at 37°C in 5 percent carbon dioxide, the supernatants were removed from some wells and frozen at −70°C for the determination of prostanoid E. The microtiter plates were frozen until the end of the study. At that time all the plates for each donor were simultaneously thawed and exposed to two more freeze-thaw cycles to complete cell lysis. The contents of triplicate wells, consisting of cell lysates and supernatants, were pooled and refrozen for determinations of interleukin-1 and tumor necrosis factor.

Determination of Interleukin-1 and Tumor Necrosis Factor

The total synthesis of cytokines (i.e., cell-associated cytokines plus secreted cytokines) was determined by radioimmunoassays for two forms of human interleukin-1 (IL-1α and IL-1β) and for tumor necrosis factor. Details on the specificity and sensitivity of each radioimmunoassay have been reported elsewhere. Each radioimmunoassay was specific for the respective cytokine. For a given stimulus, samples from all four study phases for each donor were assayed in a single radioimmunoassay for each cytokine.

Prostaglandin Determination

Prostaglandin E2 content in mononuclear-cell supernatants was determined by direct competitive radioimmunoassay. Anti-prostaglandin E2 serum, kindly provided by Dr. William Campbell (University of Texas Health Science Center at Dallas), has a cross-reactivity of 14 percent with prostaglandin E1, and of 2.7 percent with prostaglandin E3. Prostaglandin E2 standard was provided by Dr. John Pike (Upjohn, Kalamazoo, Mich.). [3H]Prostaglandin E2 was purchased from Amersham (Arlington Heights, III.). The assay does not distinguish between prostaglandin E2 and prostaglandin E3. The assay sensitivity for prostaglandin E2 is 50 pg per milliliter.

Neutrophil Chemotaxis

Polymorphonuclear neutrophils were isolated from the pellet after Ficol–Hypaque density-gradient centrifugation, and their chemotactic response to synthetic leukotriene B4 (Sigma) was assayed with use of blind well chambers, as described elsewhere. The migration distance of polymorphonuclear neutrophils was measured with the leading-front method. Each condition (buffer alone or with leukotriene B4 added at 10−3, 10−8, 10−2, and 10−6 M) was assayed in triplicate. Polymorphonuclear neutrophils from healthy subjects not receiving n-3 fatty acid supplementation were assayed in parallel (same-day control). The results are expressed as percent increases over spontaneous migration in buffer.

Fatty Acid Analyses

For the measurement of plasma fatty acids, 18 ml of blood was drawn into EDTA-coated tubes and centrifuged for 20 minutes at 8000 g. The plasma was removed and frozen at −70°C until analyzed. Lipids were extracted and methylated, as described elsewhere. For the determination of the fatty acid composition of mononuclear cells, cells obtained on three different days during each of the four study phases were pooled, for a total of 4.5X10⁶ mononuclear cells per subject. The lysates of these cells were centrifuged at 100,000 g and extracted, and the phospholipids were purified and transmethylated as described elsewhere. The fatty acid methyl esters were analyzed by gas–liquid chromatography on an HP-5980 gas chromatograph. The amounts of individual fatty acids were expressed as relative percentages, with total fatty acids set at 100 percent.

Statistical Analysis

The results are expressed as means ±SEM. Two-tailed Student's t-tests for paired samples were performed on a Clinfo software system (Bolt, Beraneck and Newman, Cambridge, Mass.). After Bonferroni–
The volunteers reported no untoward effects of ingesting the fish-oil concentrate. Compliance was confirmed by a significant increase in plasma levels of eicosapentaenoic acid, from 0.4±0.2 mg per deciliter at base line to 17.3±0.7 mg per deciliter during the sixth week of supplementation (P<0.001). Plasma eicosapentaenoic acid was still slightly increased (1.1±0.3 mg per deciliter; P = 0.035) 10 weeks after cessation of the supplement and returned to the presupplementation level (0.6±0.2 mg per deciliter) within 20 weeks after cessation of the supplement. Triglyceride levels were reduced from the presupplementation level (91±20 mg per deciliter) to 59±11 mg per deciliter) after six weeks of n-3 supplementation (P<0.040). They returned to the presupplementation levels at 10 weeks (1.09±0.23 mmol per liter [97±21 mg per deciliter]) and 20 weeks (1.04±0.14 mmol per liter [93±13 mg per deciliter]) after cessation of the supplement. Cholesterol levels and leukocyte and platelet counts did not change significantly. These data confirm previous findings on the effects of similar doses of n-3 fatty acids on plasma levels of fatty acids and on triglyceride levels.

The composition of mononuclear-cell phospholipid fatty acids was determined in the mononuclear-cell membranes of five randomly chosen volunteers during the four study phases (Table 1). After six weeks of n-3 fatty acid supplementation, there was a significant increase in eicosapentaenoic acid, from 0.7 percent before the supplement to 3.8 percent (P = 0.02), with a concomitant decrease of arachidonic acid, from 13.8 percent before the supplement to 8.6 percent (P = 0.04). Ten weeks after the end of supplementation, there was still a trend to increased eicosapentaenoic acid and decreased arachidonic acid concentrations, and the ratio of arachidonic acid to eicosapentaenoic acid remained significantly suppressed at a value of 12.0, as compared with 20.9 before supplementation (P = 0.02) and 23.9 at week 20 after cessation of the supplement. Twenty weeks after the end of supplementation, both eicosapentaenoic acid and arachidonic acid had returned to the presupplementation levels.

Table 1. Fatty Acid Composition of Mononuclear-Cell Membranes as a Percentage of Total Fatty Acid Content.*

<table>
<thead>
<tr>
<th>Fatty Acid</th>
<th>Before n-3 Supplement</th>
<th>After n-3 Supplement</th>
<th>Time After End of n-3 Supplement</th>
<th>10 Weeks</th>
<th>20 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA (n-6)</td>
<td>13.8±1.3</td>
<td>8.6±0.7</td>
<td>9.5±1.8</td>
<td>13.6±2.6</td>
<td></td>
</tr>
<tr>
<td>EPA (n-3)</td>
<td>0.7±0.1</td>
<td>3.8±0.7</td>
<td>1.0±0.2</td>
<td>0.6±0.1</td>
<td></td>
</tr>
<tr>
<td>DHA (n-3)</td>
<td>2.3±0.2</td>
<td>3.3±0.4</td>
<td>2.0±0.4</td>
<td>2.5±0.7</td>
<td></td>
</tr>
<tr>
<td>AA/EPA ratio</td>
<td>20.9±2.2</td>
<td>2.4±0.3</td>
<td>12.0±2.11</td>
<td>23.9±4.31</td>
<td></td>
</tr>
</tbody>
</table>

*Mononuclear cells were obtained from five subjects receiving dietary supplementation of n-3 fatty acids. AA denotes arachidonic acid, EPA eicosapentaenoic acid, and DHA docosapentaenoic acid.

**Decreased from presupplementation levels (P<0.04).
*No significant change from presupplementation levels.
†Decreased from presupplementation levels (P<0.05).
‡Decreased from presupplementation levels (P<0.003).
§Decreased from presupplementation levels (P<0.001).

Figure 1 shows the individual values for the production of IL-1β in vitro after the end of n-3 supplementation. At that time, mononuclear cells stimulated by 1 ng of endotoxin per milliliter produced only 4.2 ng of IL-1β per milliliter, as compared with the presupplementation level of 7.4 ng per milliliter (43 percent decrease; P = 0.048; Fig. 1). Ten weeks after the end of supplementation, IL-1β production had decreased further, to 2.9 ng per milliliter (61 percent decrease; P = 0.005).

The production of IL-1β returned to the presupplementation level 20 weeks after the end of supplemen-
Endotoxin-induced concentrations of IL-1α and tumor necrosis factor decreased in a similar pattern (Fig. 2A). IL-1α production fell from 16.0 ng per milliliter at base line to 10.9 ng per milliliter (32 percent decrease; P not significant) after 6 weeks of n-3 supplementation, and to 9.7 ng per milliliter (39 percent decrease; P = 0.022) 10 weeks after the end of supplementation. The production of tumor necrosis factor dropped from 8.5 ng per milliliter at base line to 6.6 ng per milliliter (22 percent decrease; P not significant) after 6 weeks of the supplement and to 5.1 ng per milliliter (40 percent decrease; P = 0.008) 10 weeks after the end of supplementation. Twenty weeks after the end of supplementation, the production of these cytokines had also returned to the presupplementation levels.

The proportion of monocytes in the mononuclear-cell population (after Ficoll–Hypaque separation) was 19.1±4.4 percent and did not change significantly after 6 weeks of the supplement or at 10 weeks after the end of supplementation.

The levels of interleukin-1 and tumor necrosis factor induced by the phagocytosis of heat-killed S. epidermidis were measured (Table 2). This phagocytic stimulus was four times more potent than the high dose of endotoxin (10 ng per milliliter) in inducing the production of IL-1β and tumor necrosis factor. These levels showed slight, insignificant decreases during week 6 of the n-3 supplement and at 10 weeks after the end of supplementation.

To assess the possible role of altered interleukin-1 production in mediating the effect of n-3 fatty acids during an immunologic challenge, we also measured the induction of IL-1β and IL-1α by phytohemagglutinin in the same cell population (Fig. 2B). After six weeks of n-3 supplementation, the production of IL-1α had decreased significantly, from 14.0 to 12.0 ng per milliliter (14 percent decrease; P = 0.044). During the 10th week after the end of supplementation, however, both cytokines were significantly reduced: IL-1β by 53 percent (from 3.0 to 1.4 ng per milliliter; P = 0.003), and IL-1α by 37 percent (from 14.2 to 9.0 ng per milliliter; P = 0.0001).

We studied a control group during the same interval that we studied the second group of volunteers in the first two phases of n-3 supplementation. Although endotoxin stimulation of the mononuclear cells from these control subjects produced lower amounts of IL-1β (Fig. 1, inset), the production of this cytokine at week 7 did not significantly change (102±16 percent of the levels produced at week 1). The levels of IL-1α and tumor necrosis factor were 116±10 and 90±6 percent, respectively, at week 7. At that time, cytokine production induced by S. epidermidis was 110±8 percent of the levels at week 1 for IL-1β, 100±13 percent for IL-1α, and 111±2 percent for tu-
mor necrosis factor. There was no significant change in the in vitro production of interleukin-1 and tumor necrosis factor in volunteers receiving no dietary supplementation during an interval of six weeks.

**Prostaglandin Synthesis**

In the initial group of six volunteers, prostaglandin E$_2$ release was measured in the supernatant of mononuclear cells stimulated by S. epidermidis (Fig. 3). Prostaglandin E$_2$ release decreased from 612 pg per milliliter at base line to 302 pg per milliliter after 6 weeks of supplementation (51 percent decrease; P = 0.008), to 423 pg per milliliter (P not significant) after 10 weeks of supplementation, and to 812 pg per milliliter (P not significant) after 20 weeks of supplementation. After cessation of the supplement there was no significant change in prostaglandin E$_2$ release from the presupplementation level.

**Neutrophil Chemotaxis**

Random migration of polymorphonuclear neutrophils in both the study and control subjects was unchanged at all times (data not shown). The chemotactic responses of polymorphonuclear neutrophils after six weeks of n-3 supplementation were suppressed at all four concentrations of leukotriene B$_4$. Figure 4 shows that chemotaxis to $10^{-7}$ M leukotriene B$_4$, which elicited the highest response, was 83±8.2 percent (mean of percent increase over random migration) before the n-3 supplement, 62±5.0 percent after 6 weeks of the supplement, and 79±12.5 percent 10 weeks after cessation of the supplement. The suppression of chemotaxis after six weeks of supplementation was significant as compared with the presupplementation control (P = 0.038) and with the control group assayed on the same day (94±11.9 percent; P = 0.041). This is in agreement with the findings of Lee et al., who decreased neutrophil chemotaxis in healthy volunteers whose diet was supplemented with n-3 fatty acids.

**Discussion**

Our results show that dietary supplementation with n-3 fatty acids reduces the amount of inducible production of interleukin-1 and tumor necrosis factor by mononuclear cells in vitro. The reduced production of IL-1β, IL-1α, and tumor necrosis factor may contribute to the decreased inflammatory responses reported in patients receiving n-3 supplementation.

We studied the production of interleukin-1 and tumor necrosis factor by total mononuclear cells rather than by enriched monocytes. Since monocytes, T cells, B cells, and large granular lymphocytes synthesize interleukin-1 and tumor necrosis factor, we believe that the response of the whole cell population is biologically more relevant than that of enriched subpopulations. Although we studied peripheral mononuclear cells as an accessible source, it is probable that dietary n-3 fatty acids also decrease the production of interleukin-1 and tumor necrosis factor by other types of cells, such as synovial cells, alveolar macrophages, and mesangial, vascular, and skin cells. Since we measured total interleukin-1 and tumor necrosis factor (i.e., both cell-associated and secreted), our results demonstrate that n-3 fatty acids affect the synthesis rather than the release of these cytokines.

The persistent suppression of the production of...
interleukin-1 and tumor necrosis factor by mononuclear cells for as long as 10 weeks after cessation of the n-3 supplement, accompanied by persistent fatty acid changes in these cells, was a striking phenomenon observed in both sets of volunteers. Since monocytes in the circulation had been formed in the bone marrow only a few days earlier, it is possible that our findings reflect the recycling of n-3 fatty acids from a slow-turnover compartment of fatty acids. The ratio of arachidonic acid to eicosapentaenoic acid, which was maximally suppressed immediately after n-3 supplementation, reflects the measurement of the total phospholipid fatty acid pool. This does not allow conclusions about intracellular compartments or phospholipid subclasses. Thus, we cannot exclude the altered fatty acid composition of a critical compartment at 10 weeks after the end of supplementation, when the suppression of cytokine production was maximal.

We observed functional changes in cytokine production as late as 10 weeks after n-3 supplementation was discontinued; other investigators have also observed the long persistence of biochemical changes associated with n-3 fatty acid supplementation. In a clinical trial in patients with rheumatoid arthritis, leukotriene B₄ generation in neutrophils remained below baseline levels for as long as 18 weeks after n-3 fatty acid supplementation was stopped. Concomitantly, in the crossover design of that study, the treatment group still had clinical improvement when it entered the placebo phase after a washout period of four weeks. The prolonged effects of dietary n-3 fatty acid supplementation on the production of interleukin-1 and tumor necrosis factor has implications for the design of future clinical trials. A maximal effect on mononuclear-cell cytokine production may be reached slowly during supplementation and may persist for at least 10 weeks after cessation of the supplement. This prolonged effect should be taken into account in the planning of washout periods, particularly in crossover designs.

The mechanism underlying the suppression of the synthesis of interleukin-1 and tumor necrosis factor after dietary supplementation with n-3 fatty acids remains unknown. However, alterations in the type of arachidonic acid metabolites produced during stimulation of the mononuclear cells may explain in part the decreased production of these two cytokines. The n-3 fatty acids induce changes in both cyclooxygenase and lipoxygenase products. One possible mechanism may be decreased 5-lipoxygenase metabolites such as leukotriene B₄, adding exogenous leukotriene B₄ to human mononuclear cells enhances endotoxin-stimulated production of interleukin-1. Conversely, inhibitors of 5-lipoxygenase reduce the production of interleukin-1. Supplementation with the same n-3 fatty acid preparation in the same dosage and during the same time as in the present study decreased monocyte leukotriene B₄ production by 58 percent in healthy volunteers. Thus, a possible mechanism for decreased interleukin-1 production is decreased synthesis of leukotriene B₄ and generation of the biologically less active metabolite leukotriene B₅ from eicosapentaenoic acid.

Although the clinical importance of our observations is uncertain, our findings may explain in part the antiinflammatory effects of n-3 fatty acids. Whether other unsaturated fatty acids have similar effects remains to be determined.

We are indebted to Scott F. Orencole, Steven D. Sisson, Judith R. McNamara, and Ingrid Weiss for technical assistance, to Deirdre G. Rees and Drs. Junxian Gong for fatty acid analysis, to Nick Papas and Sophia Papas for advice in the statistical analysis, to Hannes Eisele for assistance in data transmission, and to Judith Bollinger-Gruber and Drs. Jeffrey A. Gelfand, David V. Ives, Burton D. Clark, Laurie Miller, and Reinhard Lorenz for helpful discussions.

REFERENCES

We investigated the association of self-report- 
ed asthma or allergic rhinitis with serum IgE levels 
and skin-test reactivity in 2657 subjects 
aged asthma or allergic rhinitis with serum IgE levels 
and the degree of reactivity to skin tests. In contrast, aller-

gic asthma was present in the 177 subjects with the lowest 
level standardized for age and sex (P<0.0001), and no 
prevalence of asthma was closely related to the serum IgE 
level. These findings challenge the concept that there are 
both allergic (“extrinsic”) and serum IgE levels to age in the gener­

cal-population study. Regardless of the subjects’ status with respect to atopy or their age group, the 
prevailing status of asthma was closely related to the serum IgE 
level standardized for age and sex (P<0.0001), and no 
asthma was present in the 177 subjects with the lowest 
IgE levels for their age and sex (>1.46 SD below the 
mean). The log odds ratio increased linearly with the se­ 
mean). The log odds ratio increased linearly with the se­ 
level standardized for age and sex (P<0.0001), and no 
prevalence of asthma was closely related to the serum IgE 
level. These findings challenge the concept that there are 
both allergic (“extrinsic”) and serum IgE levels to age in the gener­

I T is generally accepted that there are both allergic 
and nonallergic forms of asthma, and the distinc­ 
tion is usually based on the presence or absence of 
allergy skin-test reactivity to one or more aeroal­
ergists considered capable of inducing the disease. 
Since Rackemann introduced the terms in 1918, a 
asthma that can be shown to be related to hypersensitivity 
to a foreign substance has been described as “extrin­
"; otherwise, the disease has been classified as “intrinsic.” 

After Ishizaka and Johansson and their colleagues 
identified immunoglobulin E (IgE) as the antibody 
responsible for the immediate type of immune re­ 
response, a number of authors noted marked elevations of 
IgE in young patients with asthma, and some 
have attempted to distinguish extrinsic from intrinsic 
disease on the basis of the presence or absence of an 
elevated serum concentration of IgE. Regardless of 
the specific criteria, however, extrinsic asthma ap­ 
ppears to be the predominant form of the disease 
among children and young adults, and intrinsic asth­
ma is considered to be more common among older 
subjects. These widely accepted concepts, based largely on 
clinical observations, fail to take into account the rela­
tions of both allergy skin-test reactivity (hereafter 
called atopy) and serum IgE levels to age in the gener­

ASSOCIATION OF ASThma WITH Serum IgE LEVELS AND SKIN-TEST REACTIVITY 
TO ALLERGENS 

Benjamin Burrows, M.D., Fernando D. Martinez, M.D., Marilyn Halonen, Ph.D., 
Robert A. Barbee, M.D., and Martha G. Cline, M.S.

Abstract We investigated the association of self-report­
ed asthma or allergic rhinitis with serum IgE levels and 
skin-test reactivity to allergens in 2657 subjects 
in a general-population study. Regardless of the sub­
jects’ status with respect to atopy or their age group, the 
prevalence of asthma was closely related to the serum IgE 
level standardized for age and sex (P<0.0001), and no 
asthma was present in the 177 subjects with the lowest 
IgE levels for their age and sex (>1.46 SD below the 
mean). The log odds ratio increased linearly with the se­ 

From the Division of Respiratory Sciences (Westend Laboratories), University 
of Arizona College of Medicine, Tucson, Ariz. Address reprint requests to Dr. 
Burrows at the Division of Respiratory Sciences, University of Arizona College 
of Medicine, Tucson, AZ 85724.

Supported by a Specialized Center of Research Grant (HL-14136) from the 
National Heart, Lung, and Blood Institute.

22. Weiner BH, Ockene IS, Levine PH, et al. Inhibition of atherosclerosis by 
cocopher in a hyperlipidemic swine model. N Engl J Med 1986; 315:841- 
6.

23. Davis HR, Bredenstine RT, Vesselinovitch D, Wissler RW. Fish oil inhibits 
development of atherosclerosis in fuchs monkeys. Arteriosclerosis 1987; 
7:441-9.

tion to reject human interleukin-1-induced substances derived from bacterial cul­

Development and use of a radioimmunoassay for human interleukin-1 beta. 
Lymphokine Res 1987; 6:229-44.

munoreactive human tumor necrosis factor alpha produced by human mono­ 

27. Lonemann G, Endres S, van der Meer JW, Cannon JG, Dinarello CA. A 
radioimmunoassay for human interleukin-1α. Measurement of IL-1α pro­ 
duced in vitro by human blood mononuclear cells stimulated with endo­ 

28. Georgiades K, Schaefer C, Dinarello CA, Klemperer MS. Human recombinant 
interleukin 1 beta has no effect on intraculcular calcium or on functional 

29. Siguel EN, Chee KM, Gong JX, Schaefer EJ. Criteria for essential fatty acid 
deficiency in plasma as assessed by capillary column gas-liquid chromatog­ 

omega-3 fatty acids upon plasma and cellular lipids, platelet function, and 

31. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. 
Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils 

chieri G. Independent regulation of tumor necrosis factor and lymphokine 
165:1581-94.

33. Matsushita K, Procopio A, Abe H, Scala G, Ortoldo JR, Oppenheim JJ. 
Production of interleukin 1 activity by normal human peripheral blood B 

34. Scala G, Allavena P, Djeu JY, et al. Human large granular lymphocytes are 

35. Lovett DH, Sierzel RB, Ryan JL, Atkins E. Production of an endogenous 

Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in 

37. Sauder DN. Biologic properties of epidermal cell thymocyte-activating fac­ 

38. van Furth R, Raeburn JA, van Zwer TL. Characteristics of human mononu­ 

39. Kunkel SL, Chensue SW, PHan SH. Prostaglandins as endogenous media­ 

40. Knudson PJ, Dinarello CA, Strom TB. Prostaglandins posttranscriptionally 
hibit monocyte expression of interleukin 1 activity by increasing intracul­

41. Rola-Pleszcynski M, Lemaire J. Leukotrienes augment interleukin 1 pro­

42. Dinarello CA, Bishai I, Rosenwasser LJ, Coccani F. The influence of lipox­
genase inhibitors on the in vitro production of human leukocytic pyrogen 
and lymphocyte activating factor (interleukin-1). Int J Immunopharmacol 

43. Kunkel SL, Chensue SW. Arachidonic acid metabolites regulate interleu­